{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:23:23Z","timestamp":1772166203801,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":31,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cost Eff Resour Alloc"],"DOI":"10.1186\/s12962-025-00698-6","type":"journal-article","created":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T05:31:13Z","timestamp":1767418273000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["External validation of the budget impact analysis of the drug fingolimode in the treatment of multiple sclerosis"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0970-1105","authenticated-orcid":false,"given":"Cesar Ricardo Simioni","family":"Campello","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3861-5257","authenticated-orcid":false,"given":"M\u00e1rcia Gisele Santos","family":"da Costa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7568-5014","authenticated-orcid":false,"given":"M\u00e1rcia","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,2]]},"reference":[{"key":"698_CR1","unstructured":"Machado S et al. Recomenda\u00e7\u00f5es \u2013 Esclerose M\u00faltipla. Academia Brasileira de Neurologia. 2012. S\u00e3o Paulo. Available: http:\/\/www.cadastro.abneuro.org\/site\/publico_esclerose.asp. Access: September 20, 2019."},{"key":"698_CR2","first-page":"208","volume":"104","author":"D Callegaro","year":"2001","unstructured":"Callegaro D, Goldbaum M, Morais L. The prevalence of multiple sclerosis in the City of Sao Paulo, Brazil. Acta neurol. Scand. 2001;104:208\u201313.","journal-title":"Scand"},{"issue":"4","key":"698_CR3","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1590\/S1415-790X2007000400005","volume":"10","author":"YD Fragoso","year":"2007","unstructured":"Fragoso YD, Peres M. Prevalence of multiple sclerosis in the City of Santos, S\u00e3o Paulo. Rev Bras Epidemiol. 2007;10(4):479\u201382.","journal-title":"Rev Bras Epidemiol"},{"key":"698_CR4","doi-asserted-by":"crossref","unstructured":"Ferreira M, Machado Me, Vilela L. Arq Neuro-Psiquiatr. 2004;62(4):1027\u201332. Epidemiologia de 118 casos de esclerose m\u00faltipla com seguimento de 15 anos no centro de refer\u00eancia do Hospital da Restaura\u00e7\u00e3o de Pernambuco.","DOI":"10.1590\/S0004-282X2004000600018"},{"issue":"2","key":"698_CR5","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1590\/0004-282X20130216","volume":"72","author":"AM Finkelsztejn","year":"2014","unstructured":"Finkelsztejn AM, Lopes JS. The prevalence of multiple sclerosis in Santa Maria, Rio Grande do Sul, Brazil. Arq Neuro-Psiquiatr. 2014;72(2):104\u20136.","journal-title":"Arq Neuro-Psiquiatr"},{"issue":"16","key":"698_CR6","first-page":"S307","volume":"19","author":"GM Owens","year":"2013","unstructured":"Owens GM. Managed care aspects of managing multiple sclerosis. Am J Manag Care. 2013;19(16):S307\u201312.","journal-title":"Am J Manag Care"},{"issue":"16","key":"698_CR7","first-page":"S294","volume":"19","author":"CE Markowitz","year":"2013","unstructured":"Markowitz CE. Multiple sclerosis update. Am J Manag Care. 2013;19(16):S294\u2013300.","journal-title":"Am J Manag Care"},{"key":"698_CR8","doi-asserted-by":"crossref","unstructured":"Pelletier D, Hafler D. Fingolimod for multiple sclerosis. N Engl J Med. 2012 Jan.;366(4):339\u201347.","DOI":"10.1056\/NEJMct1101691"},{"key":"698_CR9","unstructured":"Brasil, Portaria, n\u00b0493. de 23 de setembro de 2010; referente ao roteiro de elabora\u00e7\u00e3o do PCDT. Available: https:\/\/bvsms.saude.gov.br\/bvs\/saudelegis\/sas\/2010\/prt0493_23_09_2010.html. Access: March 10, 2019."},{"key":"698_CR10","unstructured":"Brasil. Minist\u00e9rio da Sa\u00fade. Comiss\u00e3o Nacional de Incorpora\u00e7\u00e3o de Tecnologias no SUS (CONITEC). Relat\u00f3rio de Recomenda\u00e7\u00e3o da Comiss\u00e3o Nacional de Incorpora\u00e7\u00e3o de Tecnologias no SUS - CONITEC n\u00b0 113 Julho\/2014. Fingolimode para o tratamento da esclerose m\u00faltipla. Available: https:\/\/docs.bvsalud.org\/biblioref\/2017\/11\/875374\/fingolimodeem_final.pdf Access: March 10. 2019."},{"key":"698_CR11","unstructured":"Minist\u00e9rio da Sa\u00fade. Secretaria de Aten\u00e7\u00e3o \u00e0 Sa\u00fade. Portaria n\u00b0 391, de 5 maio de 2015, Protocolo Clinico e Diretrizes Terap\u00eauticas \u2013 Esclerose M\u00faltipla. Available: https:\/\/www.gov.br\/saude\/pt-br\/assuntos\/protocolos-clinicos-e-diretrizes-terapeuticas-pcdt\/arquivos\/2022\/portal_portaria-conjunta-no-1-pcdt_esclerose-multipla.pdf Access: March 10. 2019."},{"key":"698_CR12","unstructured":"Brasil. Minist\u00e9rio da Sa\u00fade. Comiss\u00e3o Nacional de Incorpora\u00e7\u00e3o de Tecnologias no SUS (CONITEC). Relat\u00f3rio de Recomenda\u00e7\u00e3o da Comiss\u00e3o Nacional de Incorpora\u00e7\u00e3o de Tecnologias no SUS - CONITEC n\u00b0 257 Mar\u00e7o\/2017. Fingolimode no tratamento da esclerose m\u00faltipla remitente recorrente ap\u00f3s falha terap\u00eautica com betainterferona ou glatir\u00e2mer. Available: http:\/\/conitec.gov.br\/images\/Relatorios\/2017\/Relatorio_Fingolimode_EscleroseMultipla_final.pdf. Access: March 10, 2019."},{"key":"698_CR13","unstructured":"Minist\u00e9rio da Sa\u00fade. Secretaria de Aten\u00e7\u00e3o \u00e0 Sa\u00fade. Secretaria de Ci\u00eancia, Tecnologia e insumos Estrat\u00e9gicos. Portaria n\u00b0 10 de 02 de abril de 2018. Protocolo Cl\u00ednico de Diretrizes Terap\u00eauticas da Esclerose M\u00faltipla. Available: http:\/\/conitec.gov.br\/images\/Protocolos\/ESCLEROSE-MLTIPLA.pdf. Access: July 10, 2019."},{"key":"698_CR14","unstructured":"Brasil. Minist\u00e9rio da Sa\u00fade. Comiss\u00e3o Nacional de Incorpora\u00e7\u00e3o de tecnologias no SUS (CONITEC). Relat\u00f3rio de Recomenda\u00e7\u00e3o n\u00b0 259 \u2013 Teriflunomida para a primeira linha de tratamento da esclerose m\u00faltipla remitente recorrente. CONITEC, n\u00b0 259, abril 2017. Available: http:\/\/conitec.gov.br\/images\/Relatorios\/Relatorio_Teriflunomida_EMRR_final.pdf. Access: July 10, 2019."},{"key":"698_CR15","unstructured":"Brasil. Minist\u00e9rio da Sa\u00fade. Comiss\u00e3o Nacional de Incorpora\u00e7\u00e3o de tecnologias no SUS (CONITEC). Relat\u00f3rio de Recomenda\u00e7\u00e3o n\u00b0 286 \u2013 Fumarato de Dimetila para tratamento da esclerose m\u00faltipla remitente recorrente. CONITEC, agosto de 2017. Available: http:\/\/conitec.gov.br\/images\/Relatorios\/2017\/Relatorio_Fumarato_de_dimetila_Esclerose_Multipla_286_2017_FINAL.pdf. Access: July 10, 2019."},{"key":"698_CR16","unstructured":"Minist\u00e9rio da Sa\u00fade. Secretaria de Aten\u00e7\u00e3o \u00e0 Sa\u00fade. Secretaria de Ci\u00eancia, Tecnologia e insumos Estrat\u00e9gicos. Portaria n\u00b0 7 de 3 de julho de 2019. Protocolo Cl\u00ednico de Diretrizes Terap\u00eauticas da Esclerose M\u00faltipla. Available: http:\/\/conitec.gov.br\/images\/Protocolos\/PCDT-Esclerose-Mltipla.pdf. Access: March 05, 2021."},{"key":"698_CR17","unstructured":"Minist\u00e9rio da Sa\u00fade. Secretaria de Aten\u00e7\u00e3o \u00e0 Sa\u00fade. Secretaria de Ci\u00eancia, Tecnologia e insumos Estrat\u00e9gicos. Coordena\u00e7\u00e3o-Geral de Gest\u00e3o de Tecnologias em Sa\u00fade. Coordena\u00e7\u00e3o de Gest\u00e3o de Protocolos Cl\u00ednicos e Diretrizes Terap\u00eauticas. Relat\u00f3rio de Recomenda\u00e7\u00e3o n\u00b0582 \u2013 Protocolo Cl\u00ednico e Diretriz terap\u00eautica (Esclerose M\u00faltipla). Bras\u00edlia 2020. Dezembro. Available: http:\/\/conitec.gov.br\/images\/Relatorios\/2021\/20210409_Relatorio_Recomendacao_582_PCDT_EMRR.pdf. Access: September 08, 2021."},{"issue":"6","key":"698_CR18","doi-asserted-by":"publisher","first-page":"609","DOI":"10.2165\/00019053-200119060-00001","volume":"19","author":"P Trueman","year":"2001","unstructured":"Trueman P, Drummond M, Hutton J. Developing guidance for budget impact analysis. PharmacoEconomics. 2001;19(6):609\u201321.","journal-title":"PharmacoEconomics"},{"key":"698_CR19","doi-asserted-by":"crossref","unstructured":"Mauskopf JA, Sullivan SD, Annemans L. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices \u2013 budget impact analysis. Value Health 2007 sep-oct; 10 (5): pp. 336\u2009\u2013\u200947.","DOI":"10.1111\/j.1524-4733.2007.00187.x"},{"key":"698_CR20","doi-asserted-by":"crossref","unstructured":"Costa MG, Luna LC, Leite PH, Tura BR, Pinto M, e Santos M. Revis\u00e3o e Atualiza\u00e7\u00e3o Da metodologia de An\u00e1lise de impacto Or\u00e7ament\u00e1rio de tecnologia de Sa\u00fade Para o SUS. J Bras Econ Sa\u00fade 2019 Abril. 11(1): 73\u201386.","DOI":"10.21115\/JBES.v11.n1.p73-86"},{"key":"698_CR21","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.jval.2012.04.012","volume":"15","author":"DM Eddy","year":"2012","unstructured":"Eddy DM, Hollingworth W, Caro J, Tsevat J, McDonald KM, Wong JB. Model transparency and validation: A report of the ISPOR-SMDM modeling good research practices task Forces-7. Value Health. 2012;15:843\u201350.","journal-title":"Value Health"},{"key":"698_CR22","unstructured":"Sistema de Informa\u00e7\u00f5es ambulatorial do SUS (SAI\/SUS). Available: http:\/\/www.meuprontuario.net\/2012\/02\/21\/siasus-sistema-de-informacao-ambulatorial\/#:~:text=O%20SISTEMA%20DE%20INFORMA%C3%87%C3%83O%20AMBULATORIAL,tomada%20de%20decis%C3%B5es%20em%20sa%C3%BAde. Access: December 30, 2021."},{"key":"698_CR23","unstructured":"Moon S, Page S, Rodin B, Roy D. Purchasing power parity measures: advantages and limitations. Overseas Development Institute. 2010, June. (Background Note, ISSN 1756\u20137610). Available at http:\/\/www.odi.org.uk. Accessed October 15, 2025."},{"key":"698_CR24","unstructured":"Brasil. Minist\u00e9rio da Sa\u00fade. Diretrizes Metodol\u00f3gicas \u2013 An\u00e1lise de Impacto Or\u00e7ament\u00e1rio \u2013 Manual para o Sistema de Sa\u00fade do Brasil. 1\u00b0 edi\u00e7\u00e3o. Bras\u00edlia \u2013DF- 2014. Available: https:\/\/portalarquivos2.saude.gov.br\/images\/pdf\/2014\/novembro\/10\/Diretrizes-metodologicas-manual-de-analise-de-impacto-orcamentario-cienciasus.pdf. Access: March 10, 2019."},{"key":"698_CR25","doi-asserted-by":"crossref","unstructured":"Pereira AB, Lacativa MC, Pereira FF, Alvarenga RM Prevelence of multiple sclerosis in Brazil: a systematic review. Mult Scler Relat Disord. 2015;4:572-579.","DOI":"10.1016\/j.msard.2015.08.004"},{"key":"698_CR26","doi-asserted-by":"crossref","unstructured":"Marques VD, Passos GR, Mendes MF, Callegaro D, Lana-Peixoto MA, Comini-Frota ER et al. Brazilian Consensus for the Treatment of Multiple Sclerosis: Brazilian Academy of Neurology and Brazilian Committee on Treatment and Research in Multiple Sclerosis. Arq Neuropsiquiatr. 2018;76(8):539\u2013554.","DOI":"10.1590\/0004-282x20180078"},{"key":"698_CR27","doi-asserted-by":"crossref","unstructured":"Braune S, Lang M, Bergmann A. Efficacy of fingolimod is superior to injectable disease modifying therapies in second-line therapy of relapsing remitting multiple sclerosis. J.Neurol. 2016. Feb 8;263(2):327\u2013333.","DOI":"10.1007\/s00415-015-7970-6"},{"key":"698_CR28","doi-asserted-by":"crossref","unstructured":"Fox E, Edwards K, Burch G, Wynn DR, LaGanke C, Crayton H, et al. Outcomes of switching directly to oral fingolimod from injectable therapies: results of the randomized, open-label, multicenter, evaluate patient outcomes (EPOC) study in relapsing multiple sclerosis. Mult Scler Relat Disord. 2014. Sep;3(5):607\u201319.","DOI":"10.1016\/j.msard.2014.06.005"},{"issue":"12","key":"698_CR29","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.1007\/s00415-015-7834-0","volume":"262","author":"X Montalban","year":"2015","unstructured":"Montalban X, Comi G, Antel J, O\u2019Connor P, de Vera A, Cremer M, et al. Long-term results from a phase 2 extension study of Fingolimod at high and approved dose in relapsing multiple sclerosis. J Neurol. 2015;262(12):2627\u201334.","journal-title":"J Neurol"},{"key":"698_CR30","unstructured":"Brasil. Minist\u00e9rio da Sa\u00fade. Sistema de Gerenciamento da Tabela de Procedimentos, Medicamentos e OPM do SUS. Compet\u00eancia setembro\/2019. Available: http:\/\/sigtap.datasus.gov.br\/tabela-unificada\/app\/sec\/inicio.jsp. Access: September 20, 2019."},{"key":"698_CR31","unstructured":"CARVALHO DM. Grandes sistemas nacionais de informa\u00e7\u00e3o em sa\u00fade: revis\u00e3o e discuss\u00e3o atual. Informe Epidemiol\u00f3gico do SUS, Bras\u00edlia. 1997;6(4):7\u201346."}],"container-title":["Cost Effectiveness and Resource Allocation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12962-025-00698-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12962-025-00698-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12962-025-00698-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T13:56:36Z","timestamp":1770040596000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12962-025-00698-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,2]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["698"],"URL":"https:\/\/doi.org\/10.1186\/s12962-025-00698-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4578355\/v1","asserted-by":"object"}]},"ISSN":["1478-7547"],"issn-type":[{"value":"1478-7547","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,2]]},"assertion":[{"value":"13 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This is a validation study with public data, available in public databases. No ethical approval is required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23"}}